add directory ♦ physical therapy jobs
Today's News:
All Neurology Jobs
Permanent Neurology Job in Northern Michigan with Medical Search International
Seeking a Neurologist for a prestigious regional medical center in Northern Michigan. The ideal candidate will be Board Certified or Board Eligible in Neurology. The Neurologist will be part of a team
Permanent Neurology Job in Nashville Suburb Iowa with Nationwide Physician Recruitment
Excellent opportunity in a great community of 23,000 - only 28 miles to downtown Nashville. Wonderful place to live and practice. Solo private practice opportunity with an income guarantee for 12 months.
Permanent Neurology Job in Upstate New York with Booth-Yellin Physician Recruitment
A upstate multi-specialty group has a opening for BE-BC Neurologist. Candidate should have sub specialty training in stroke, epilepsy, movement disorders or headache pain and will do EMG's. The Neurology
Archives of Neurology recent issues
ORIGINAL CONTRIBUTION: Heterogeneity in Response to Interferon Beta in Patients With Multiple Sclerosis: A 3-Year Monthly Imaging Study
Chiu, A. W., Richert, N., Ehrmantraut, M., Ohayon, J., Gupta, S., Bomboi, G., Gaindh, D., Cantor, F. K., Frank, J. A., McFarland, H. F., Bagnato, F. Mon, 10 Nov 2008 00:00:00 -0000
Objectives To investigate the heterogeneity in magnetic resonance image (MRI) patterns of response to interferon beta across patients with multiple sclerosis or within an individual patient over time.Design, Setting, and Patients Fifteen patients with relapsing-remitting multiple sclerosis underwent monthly MRIs and clinical examinations (6-month pretherapy phase and 36-month therapy phase) and bimonthly neutralizing antibody tests. On each MRI, the total number of contrast-enhancing lesions was noted. Therapy MRI responders were defined as those with a reduction of 60% or more in the total number of contrast-enhancing lesions during each semester of therapy.Intervention Subcutaneous administration of interferon beta-1b, 250 µg, every other day for 3 years.Main Outcome Measure Reduction in the number of contrast-enhancing lesions.Results Eight patients (53.3%) were MRI responders and 7 (46.7%) were nonresponders. Of those 7, 3 (20.0%) had only an initial optimal reduction of the total number of contrast-enhancing lesions, 2 (13.3%) never reached an optimal response, and 2 (13.3%) had a delayed optimal response. No clear association between neutralizing antibody profile and MRI response was evident.Conclusions Multiple MRI evaluations disclose that approximately only half of the patients treated with interferon beta achieve and maintain a full response to the drug over time, although an additional small number of individuals may still restore an optimal response to the drug after an initial failure.Published online November 10, 2008 (doi:10.1001/archneur.66.1.noc80047).
ORIGINAL CONTRIBUTION: Decrease in the Numbers of Dendritic Cells and CD4+ T Cells in Cerebral Perivascular Spaces Due to Natalizumab
Martin, M. d. P., Cravens, P. D., Winger, R., Frohman, E. M., Racke, M. K., Eagar, T. N., Zamvil, S. S., Weber, M. S., Hemmer, B., Karandikar, N. J., Kleinschmidt-DeMasters, B.K., Stuve, O. Mon, 13 Oct 2008 00:00:00 -0000
Objective To extend our studies on the prolonged and differential effect of natalizumab on T lymphocyte numbers in the cerebrospinal fluid, we investigated the number and phenotypes of leukocytes and the expression of major histocompatibility complex (MHC) classes I and II in cerebral perivascular spaces (CPVS). We hypothesized that natalizumab reduces the number of antigen presenting cells in CPVS.Design A case-control study in which inflammatory cell numbers in the CPVS of cerebral tissue were assessed by immunohistochemical staining.Subjects A patient with multiple sclerosis (MS) who developed progressive multifocal leukoencephalopathy (PML) during natalizumab therapy. Controls included location-matched cerebral autopsy material of patients without disease of the central nervous system, patients with MS not treated with natalizumab, and patients with PML not associated with natalizumab therapy.Results The absolute number of CPVS in the patient with MS treated with natalizumab was significantly lower than in the control groups owing to extensive destruction of the tissue architecture. The expression of MHC class II molecules and the number of CD209+ dendritic cells were significantly decreased in the CPVS of the patient with MS treated with natalizumab. No CD4+ T cells were detectable.Conclusions Our observations may explain the differential and prolonged effects of natalizumab therapy on leukocyte numbers in the cerebrospinal fluid.Published online October 13, 2008 (doi:10.1001/archneur.65.12.noc80051).
ABOUT THIS JOURNAL: About This Journal
Mon, 10 Nov 2008 00:00:00 -0000
Subscribe to Pediatric RSS feed 
Permanent Neurology Job in Northern Michigan with Medical Search International
Seeking a Neurologist for a prestigious regional medical center in Northern Michigan. The ideal candidate will be Board Certified or Board Eligible in Neurology. The Neurologist will be part of a team
Permanent Neurology Job in Nashville Suburb Iowa with Nationwide Physician Recruitment
Excellent opportunity in a great community of 23,000 - only 28 miles to downtown Nashville. Wonderful place to live and practice. Solo private practice opportunity with an income guarantee for 12 months.
Permanent Neurology Job in Upstate New York with Booth-Yellin Physician Recruitment
A upstate multi-specialty group has a opening for BE-BC Neurologist. Candidate should have sub specialty training in stroke, epilepsy, movement disorders or headache pain and will do EMG's. The Neurology
Archives of Neurology recent issues
ORIGINAL CONTRIBUTION: Heterogeneity in Response to Interferon Beta in Patients With Multiple Sclerosis: A 3-Year Monthly Imaging Study
Chiu, A. W., Richert, N., Ehrmantraut, M., Ohayon, J., Gupta, S., Bomboi, G., Gaindh, D., Cantor, F. K., Frank, J. A., McFarland, H. F., Bagnato, F. Mon, 10 Nov 2008 00:00:00 -0000
Objectives To investigate the heterogeneity in magnetic resonance image (MRI) patterns of response to interferon beta across patients with multiple sclerosis or within an individual patient over time.Design, Setting, and Patients Fifteen patients with relapsing-remitting multiple sclerosis underwent monthly MRIs and clinical examinations (6-month pretherapy phase and 36-month therapy phase) and bimonthly neutralizing antibody tests. On each MRI, the total number of contrast-enhancing lesions was noted. Therapy MRI responders were defined as those with a reduction of 60% or more in the total number of contrast-enhancing lesions during each semester of therapy.Intervention Subcutaneous administration of interferon beta-1b, 250 µg, every other day for 3 years.Main Outcome Measure Reduction in the number of contrast-enhancing lesions.Results Eight patients (53.3%) were MRI responders and 7 (46.7%) were nonresponders. Of those 7, 3 (20.0%) had only an initial optimal reduction of the total number of contrast-enhancing lesions, 2 (13.3%) never reached an optimal response, and 2 (13.3%) had a delayed optimal response. No clear association between neutralizing antibody profile and MRI response was evident.Conclusions Multiple MRI evaluations disclose that approximately only half of the patients treated with interferon beta achieve and maintain a full response to the drug over time, although an additional small number of individuals may still restore an optimal response to the drug after an initial failure.Published online November 10, 2008 (doi:10.1001/archneur.66.1.noc80047).
ORIGINAL CONTRIBUTION: Decrease in the Numbers of Dendritic Cells and CD4+ T Cells in Cerebral Perivascular Spaces Due to Natalizumab
Martin, M. d. P., Cravens, P. D., Winger, R., Frohman, E. M., Racke, M. K., Eagar, T. N., Zamvil, S. S., Weber, M. S., Hemmer, B., Karandikar, N. J., Kleinschmidt-DeMasters, B.K., Stuve, O. Mon, 13 Oct 2008 00:00:00 -0000
Objective To extend our studies on the prolonged and differential effect of natalizumab on T lymphocyte numbers in the cerebrospinal fluid, we investigated the number and phenotypes of leukocytes and the expression of major histocompatibility complex (MHC) classes I and II in cerebral perivascular spaces (CPVS). We hypothesized that natalizumab reduces the number of antigen presenting cells in CPVS.Design A case-control study in which inflammatory cell numbers in the CPVS of cerebral tissue were assessed by immunohistochemical staining.Subjects A patient with multiple sclerosis (MS) who developed progressive multifocal leukoencephalopathy (PML) during natalizumab therapy. Controls included location-matched cerebral autopsy material of patients without disease of the central nervous system, patients with MS not treated with natalizumab, and patients with PML not associated with natalizumab therapy.Results The absolute number of CPVS in the patient with MS treated with natalizumab was significantly lower than in the control groups owing to extensive destruction of the tissue architecture. The expression of MHC class II molecules and the number of CD209+ dendritic cells were significantly decreased in the CPVS of the patient with MS treated with natalizumab. No CD4+ T cells were detectable.Conclusions Our observations may explain the differential and prolonged effects of natalizumab therapy on leukocyte numbers in the cerebrospinal fluid.Published online October 13, 2008 (doi:10.1001/archneur.65.12.noc80051).
ABOUT THIS JOURNAL: About This Journal
Mon, 10 Nov 2008 00:00:00 -0000
Sites:
Archives Topic Collection: Pediatric Neurology: A searchable list of recent and archived articles on this subject, collated from the Journal of the American Medical Association.Child Neurology Society: Non-profit professional association of pediatric neurologists in the United States, Canada, and worldwide.
Danish Neuropediatric Society: Dansk Neuropćdiatrisk Selskab
Department of Pediatric Neurology: Department of Pediatric Neurology [Ljubljana, Slovenia]
Evaluation of the Child with Global Developmental Delay: The American Academy of Neurology and the Child Neurology Society offer evidence-based recommendations and an algorithm for assessing non-progressive conditions.
Medical Treatment of Infantile Spasms: A report of the American Academy of Neurology and the Child Neurology Society presents best practice guidelines for dealing with this condition and avoiding retinal toxicity.
Pediatric Neurology: Treating children with neurological disorders is often different from treating adults. The University of Virginia's team of pediatric neurologists offer comprehensive diagnostic evaluation and outpatient management of neurologic disorders in infants and children under the age of 18.
Pediatric Neurology and Metabolic deseases: ,,,,Neurologie pédiatrique et maladies métaboliques. Site du service de soins et de recherche de l'hôpital Robert-Debré à Paris. Dirigés par le Pr Philippe Evrard, les docteurs Hélène Ogier, Isabelle Husson, Alexis Arzimanoglou, Jean Aicardi et Pierre Gressens.
Pharmacological Treatment of Migraine Headache in Children and Adolescents: A literature review from the American Academy of Neurology and the Child Neurology Society investigated the use of preventive agents and the contribution of other health conditions and food ingredients.
This directory is based on the Open Directory and may have been modified
